GLP-1 Medications Like Semaglutide Do Not Increase Pancreatitis Risk and Are Linked to Fewer Complications in Diabetic Patients | Research

The takeaway

In a large multicenter study of over 740,000 type 2 diabetes patients, GLP-1 receptor agonists did not increase the risk of acute pancreatitis and were associated with significantly lower complications and 55% lower all-cause mortality.

55% lower all-cause mortality
Type 2 diabetes patients using GLP-1 receptor agonists had significantly lower all-cause mortality (HR 0.45) compared to matched patients not taking these medications, based on over 20,000 matched pairs.

What the researchers found

Among 740,370 type 2 diabetes patients (20,459 matched pairs), GLP-1 receptor agonist users showed no increased risk of developing acute pancreatitis. When pancreatitis did occur, GLP-1 RA users had dramatically better outcomes:

- Complicated pancreatitis: 68% lower risk (HR 0.32, 95% CI 0.14-0.74)

- Parenteral nutrition needs: 72% lower (HR 0.28, 95% CI 0.09-0.83)

- Sepsis: 29% lower (HR 0.71, 95% CI 0.59-0.84)

- Acute kidney injury: 46% lower (HR 0.54, 95% CI 0.49-0.60)

- Shock: 48% lower (HR 0.52, 95% CI 0.36-0.75)

- Mechanical ventilation: 77% lower (HR 0.23, 95% CI 0.16-0.33)

- All-cause mortality: 55% lower (HR 0.45, 95% CI 0.41-0.49)

The trend toward lower uncomplicated pancreatitis risk (HR 0.71) did not reach statistical significance (95% CI 0.49-1.01).

Why it matters

Pancreatitis concerns have been a persistent safety question for GLP-1 medications since their introduction. With millions of people now taking semaglutide, liraglutide, and tirzepatide for diabetes and weight loss, this large real-world study provides reassuring evidence that these drugs do not increase pancreatitis risk — and may actually be protective when pancreatitis does occur.

How the study worked

This was a retrospective cohort study using the TriNetX multicenter database. Researchers identified type 2 diabetes patients who received GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, or tirzepatide) between January 2015 and October 2023. These were matched 1:1 with non-GLP-1 RA users using propensity matching for age, demographics, comorbidities, and medications. Known pancreatitis causes (alcohol, trauma, biliary, drug-induced, hypertriglyceridemia, post-ERCP) were excluded to reduce confounding. Cox proportional hazards models estimated hazard ratios.

What this study cannot tell us

This is a retrospective observational study, which cannot establish causation. Despite propensity matching, unmeasured confounders may exist. The TriNetX database may have coding and documentation biases. The study excluded common pancreatitis causes, which improves specificity but limits generalizability. The mechanisms behind the protective effects remain unknown and require prospective studies to confirm.

How to read the evidence

This is a large retrospective cohort study with propensity-matched controls using a multicenter database. While it provides strong real-world evidence with a substantial sample size (740,370 patients), it is observational and cannot prove causation. It ranks below randomized controlled trials but above case series and case reports.

When this study was published

Published in 2026, this is a very recent study covering patient data from 2015 to 2023, making it highly current and relevant to the ongoing discussion about GLP-1 RA safety.

The bigger picture

This study addresses one of the most debated safety concerns around GLP-1-based therapies. As these medications expand from diabetes treatment into obesity, cardiovascular protection, and potentially Alzheimer's and addiction, understanding their safety profile becomes increasingly important. The finding that GLP-1 RAs may actually reduce pancreatitis complications suggests potential anti-inflammatory benefits beyond their primary metabolic effects.

Questions still open

What biological mechanisms explain why GLP-1 receptor agonists appear to reduce pancreatitis complications and mortality?
Do the protective effects differ between specific GLP-1 RA medications (semaglutide vs. liraglutide vs. tirzepatide)?
Would these findings hold up in a prospective randomized controlled trial specifically designed to assess pancreatitis outcomes?

Common questions

Do GLP-1 medications like Ozempic or Wegovy increase the risk of pancreatitis?

According to this large study of over 740,000 type 2 diabetes patients, GLP-1 receptor agonists (including semaglutide, which is the active ingredient in Ozempic and Wegovy) do not increase the risk of acute pancreatitis. In fact, when pancreatitis did occur, patients taking GLP-1 medications had significantly fewer complications and 55% lower overall mortality.

How strong is the evidence that GLP-1 medications are safe regarding pancreatitis?

This multicenter study analyzed over 20,000 propensity-matched patient pairs and found consistent protective signals across multiple outcomes (complications, organ failure, mortality). While these results are reassuring, this is an observational study — not a randomized controlled trial — so the findings show association rather than proof of causation. The authors recommend prospective studies to confirm these results.

Read the original research

Glucagon-Like Peptide-1 Receptor Agonists Use Does Not Increase the Risk for Acute Pancreatitis and Is Associated With Lower Complications in Patients With Type 2 Diabetes Who Develop Acute Pancreatitis: A Multicenter Analysis.

The American journal of gastroenterology, 121(2), 424-431

View on PubMed ↗Publisher’s paper ↗

Citation

Nieto, Luis M; Martinez, John; Narvaez, Sharon I; Ko, Donghyun; Kim, Do Han; Vega, Kenneth J; Chawla, Saurabh. (2026). Glucagon-Like Peptide-1 Receptor Agonists Use Does Not Increase the Risk for Acute Pancreatitis and Is Associated With Lower Complications in Patients With Type 2 Diabetes Who Develop Acute Pancreatitis: A Multicenter Analysis.. The American journal of gastroenterology, 121(2), 424-431. https://doi.org/10.14309/ajg.0000000000003525